- AU$62.36m
- AU$48.99m
Annual income statement for Imugene, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18.6 | 38 | 39.8 | 154 | 70.9 |
| Operating Profit | -18.6 | -38 | -39.8 | -154 | -70.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -18.5 | -37.9 | -37.9 | -150 | -69 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18.5 | -37.9 | -37.9 | -150 | -69 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18.5 | -37.9 | -37.9 | -150 | -69 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.5 | -37.9 | -37.9 | -150 | -69 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.134 | -0.227 | -0.205 | -0.664 | -0.315 |